TW200735874A - Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure - Google Patents

Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure

Info

Publication number
TW200735874A
TW200735874A TW095141963A TW95141963A TW200735874A TW 200735874 A TW200735874 A TW 200735874A TW 095141963 A TW095141963 A TW 095141963A TW 95141963 A TW95141963 A TW 95141963A TW 200735874 A TW200735874 A TW 200735874A
Authority
TW
Taiwan
Prior art keywords
asymptomatic
occult
heart failure
treatment
pde iii
Prior art date
Application number
TW095141963A
Other languages
English (en)
Chinese (zh)
Inventor
Rainer Kleemann
Christian Troetschel
Andrea Vollmar
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200735874(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of TW200735874A publication Critical patent/TW200735874A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095141963A 2005-11-14 2006-11-13 Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure TW200735874A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05110689 2005-11-14

Publications (1)

Publication Number Publication Date
TW200735874A true TW200735874A (en) 2007-10-01

Family

ID=37744668

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095141963A TW200735874A (en) 2005-11-14 2006-11-13 Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure

Country Status (13)

Country Link
US (2) US20070112010A1 (enExample)
EP (2) EP1951227B1 (enExample)
JP (1) JP5312034B2 (enExample)
CN (2) CN101309685A (enExample)
AR (1) AR056800A1 (enExample)
AU (1) AU2006310997B2 (enExample)
CA (1) CA2629367C (enExample)
DK (1) DK1951227T3 (enExample)
ES (1) ES2631879T3 (enExample)
HU (1) HUE033546T2 (enExample)
PL (1) PL1951227T3 (enExample)
TW (1) TW200735874A (enExample)
WO (1) WO2007054514A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CA2723372A1 (en) * 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
EP2702987A1 (en) 2008-11-25 2014-03-05 Boehringer Ingelheim Vetmedica GmbH Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
EP2825159B1 (en) * 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP3865120B1 (en) 2013-07-19 2025-06-25 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) * 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
PT3439660T (pt) * 2016-06-01 2024-07-18 Boehringer Ingelheim Vetmedica Gmbh Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
ES2031821T3 (es) * 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
DE60237696D1 (de) * 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

Also Published As

Publication number Publication date
EP3210605A1 (en) 2017-08-30
PL1951227T3 (pl) 2017-09-29
JP2009515927A (ja) 2009-04-16
JP5312034B2 (ja) 2013-10-09
CN102784394A (zh) 2012-11-21
CA2629367A1 (en) 2007-05-18
US20070112010A1 (en) 2007-05-17
DK1951227T3 (en) 2017-07-10
AU2006310997B2 (en) 2013-01-10
US20100273807A1 (en) 2010-10-28
AR056800A1 (es) 2007-10-24
CA2629367C (en) 2016-05-03
HUE033546T2 (hu) 2017-12-28
ES2631879T3 (es) 2017-09-05
WO2007054514A2 (en) 2007-05-18
EP1951227B1 (en) 2017-04-12
WO2007054514A3 (en) 2007-09-07
EP1951227A2 (en) 2008-08-06
CN101309685A (zh) 2008-11-19
AU2006310997A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
TW200602022A (en) Use of PDE III inhibitor for the reduction of heart size in mammals suffering from heart failure
TW200735874A (en) Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US9901568B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
ES2928408T3 (es) Métodos para el tratamiento de enfermedades fibróticas
NO20071512L (no) Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor.
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
JP2018507244A (ja) 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬
JP2020514352A (ja) 組合せ療法のための医薬組成物
WO2007062186A3 (en) Methods of using small molecule compounds for neuroprotection
ECSP099501A (es) Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
JP2010530901A5 (enExample)
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
MEP54608A (en) Arylmethylamine derivatives for use as tryptase inhibitors
Hjermitslev et al. Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension
RU2009111378A (ru) Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
CN119136793A (zh) 胆汁酸和苯基丁酸与cyp p450或转运蛋白底物用于治疗肌萎缩侧索硬化症
MY148125A (en) Compounds
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
WO2008005352A3 (en) Solid dose formulations of a thrombin receptor antagonist
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal